Published in Hepatitis Weekly, November 4th, 2002
They presented the first clinical data at the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) from a blinded, placebo-controlled phase I/II trial of Beta-L-Fd4C (ACH-126,443), Achillion Pharmaceuticals' novel L-nucleoside. Beta-L-Fd4C was well-tolerated throughout the 14-day study, the scientists said..
Beta-L-Fd4C has been shown to be a potent inhibitor of the replication of hepatitis B virus in human...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.